Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery

被引:140
作者
Mehta, Rajendra H.
Roe, Matthew T.
Mulgund, Jyotsna
Ohman, E. Magnus
Cannon, Christopher P.
Gibler, W. Brian
Pollack, Charles V., Jr.
Smith, Sidney C., Jr.
Ferguson, T. Bruce
Peterson, Eric D.
机构
[1] Duke Clin Res Inst, Durham, NC 27715 USA
[2] Div Cardiol, Durham, NC USA
[3] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA
[4] Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA
[5] Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA
[6] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
[7] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA
关键词
D O I
10.1016/j.jacc.2006.04.029
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES We sought to characterize patterns of clopidogrel use before coronary artery bypass grafting (CABG) and examine the drug's impact on risks for postoperative transfusions among patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS). BACKGROUND Adherence in community practice to American College of Cardiology/American Heart Association guidelines for clopidogrel use among NSTE ACS patients has not been previously characterized. METHODS We evaluated 2,858 NSTE ACS patients undergoing CABG at 264 hospitals participating in the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) Initiative. We examined the patterns of acute clopidogrel therapy and its association with bleeding risks among those having "early" CABG <= 5 days and again among those having "late" surgery > 5 days after catheterization. RESULTS Within 24 h of admission, 852 patients (30%) received clopidogrel. In contrast to national guidelines, 87% of clopidogrel-treated patients underwent CABG <= 5 days after treatment. Among those receiving CABG within <= 5 days of last treatment, the use of clopidogrel was associated with a significant increase in blood transfusions (65.0% vs. 56.9%, adjusted odds ratio [OR] 1.36, 95% confidence interval [CI] 1.10 to 1.68) as well as the need for transfusion of >= 4 U of blood (27.7% vs. 18.4%, OR 1.70, 95% Cl 1.32 to 2.19). In contrast, acute clopidogrel therapy was not associated with higher bleeding risks if CABG was delayed > 5 days (adjusted OR 1.18, 95% Cl 0.54 to 2.58). CONCLUSIONS Despite guideline recommendations, the overwhelming majority of NSTE ACS patients treated with acute clopidogrel needing CABG have their surgery within <= 5 days of treatment. A failure to delay surgery is associated with increased blood transfusion requirements that must be weighed against the potential clinical and economic impacts of such delays.
引用
收藏
页码:281 / 286
页数:6
相关论文
共 12 条
[1]   Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes - Results from the CRUSADE quality improvement initiative [J].
Bhatt, DL ;
Roe, MT ;
Peterson, ED ;
Li, Y ;
Chen, AY ;
Harrington, RA ;
Greenbaum, AB ;
Berger, PB ;
Cannon, CP ;
Cohen, DJ ;
Gibson, CM ;
Saucedo, JF ;
Kleiman, NS ;
Hochman, JS ;
Boden, WE ;
Brindis, RG ;
Peacock, WF ;
Smith, SC ;
Pollack, CV ;
Gibler, WB ;
Ohman, EM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (17) :2096-2104
[2]   EFFECTS OF PROFOUND PLATELET INHIBITION WITH C7E3 BEFORE CORONARY ANGIOPLASTY ON COMPLICATIONS OF CORONARY-BYPASS SURVEY [J].
BOEHRER, JD ;
KEREIAKES, DJ ;
NAVETTA, FI ;
CALIFF, RM ;
TOPOL, EJ .
AMERICAN JOURNAL OF CARDIOLOGY, 1994, 74 (11) :1166-1170
[3]   ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-Segment elevation myocardial infarction - Summary article - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina) [J].
Braunwald, E ;
Antman, EM ;
Beasley, JW ;
Califf, RM ;
Cheitlin, MD ;
Hochman, JS ;
Jones, RH ;
Kereiakes, D ;
Kupersmith, J ;
Levin, TN ;
Pepine, CJ ;
Schaeffer, JW ;
Smith, EE ;
Steward, DE ;
Theroux, P ;
Gibbons, RJ ;
Alpert, JS ;
Faxon, DP ;
Fuster, V ;
Gregoratos, G ;
Hiratzka, LF ;
Jacobs, AK ;
Smith, SC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (07) :1366-1374
[4]   Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting [J].
Chen, LQ ;
Bracey, AW ;
Radovancevic, R ;
Cooper, JR ;
Collard, CD ;
Vaughn, WK ;
Nussmeier, NA .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2004, 128 (03) :425-431
[5]   Impact of clopidogrel in coronary artery bypass grafting [J].
Englberger, L ;
Faeh, B ;
Berdat, PA ;
Eberli, F ;
Meier, B ;
Carrel, T .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2004, 26 (01) :96-100
[6]   Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical Revascularization for non-ST-elevation acute coronary syndrome - The Clopidogrel in Unstable Angina to prevent Recurrent Ischemic Events (CURE) trial [J].
Fox, KAA ;
Mehta, SR ;
Peters, R ;
Zhao, F ;
Lakkis, N ;
Gersh, BJ ;
Yusuf, S .
CIRCULATION, 2004, 110 (10) :1202-1208
[7]   APROTININ REDUCES CLOPIDOGREL-INDUCED PROLONGATION OF THE BLEEDING-TIME IN THE RAT [J].
HERBERT, JM ;
BERNAT, A ;
MAFFRAND, JP .
THROMBOSIS RESEARCH, 1993, 71 (06) :433-441
[8]   The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting [J].
Hongo, RH ;
Ley, J ;
Dick, SE ;
Yee, RR .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (02) :231-237
[9]  
LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
[10]   Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes - Insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA guidelines?) [J].
Sonel, AF ;
Good, CB ;
Mulgund, J ;
Roe, MT ;
Gibler, WB ;
Smith, SC ;
Cohen, MG ;
Pollack, CV ;
Ohman, EM ;
Peterson, ED .
CIRCULATION, 2005, 111 (10) :1225-1232